{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:28:35Z","timestamp":1783034915412,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,4,4]],"date-time":"2015-04-04T00:00:00Z","timestamp":1428105600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s11095-015-1684-4","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T19:06:53Z","timestamp":1428088013000},"page":"3029-3043","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model"],"prefix":"10.1007","volume":"32","author":[{"given":"Anthony S.","family":"Malamas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Haaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Rong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,4]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrclinonc.2012.2","volume":"9","author":"JP O\u2019Connor","year":"2012","unstructured":"O\u2019Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol. 2012;9:167\u201377.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"1684_CR2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/crad.2001.0762","volume":"56","author":"AR Padhani","year":"2001","unstructured":"Padhani AR, Husband JE. Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol. 2001;56(8):607\u201320.","journal-title":"Clin Radiol"},{"key":"1684_CR3","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039\u201349.","journal-title":"N Engl J Med"},{"key":"1684_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/35025220","volume":"407","author":"P Carmeliet","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249\u201357.","journal-title":"Nature"},{"key":"1684_CR5","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1088\/0031-9155\/57\/2\/R1","volume":"57","author":"SP Sourbron","year":"2012","unstructured":"Sourbron SP, Buckley DL. Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys Med Biol. 2012;57:R1\u201333.","journal-title":"Phys Med Biol"},{"key":"1684_CR6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/jmri.22795","volume":"34","author":"TS Koh","year":"2011","unstructured":"Koh TS, Bisdas S, Koh DM, Thng CH. Fundamentals of tracer kinetics for dynamic contrast-enhanced MRI. J Magn Reson Imaging JMRI. 2011;34:1262\u201376.","journal-title":"J Magn Reson Imaging JMRI"},{"key":"1684_CR7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/mrm.21791","volume":"60","author":"Y Feng","year":"2008","unstructured":"Feng Y, Jeong EK, Mohs AM, Emerson L, Lu ZR. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice. Magn Reson Med. 2008;60:1347\u201352.","journal-title":"Magn Reson Med"},{"key":"1684_CR8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jmri.1880070110","volume":"7","author":"R Brasch","year":"1997","unstructured":"Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, et al. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. JMRI. 1997;7:68\u201374.","journal-title":"JMRI"},{"key":"1684_CR9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ejrad.2006.06.025","volume":"60","author":"T Barrett","year":"2006","unstructured":"Barrett T, Kobayashi H, Brechbiel M, Choyke PL. Macromolecular MRI contrast agents for imaging tumor angiogenesis. Eur J Radiol. 2006;60:353\u201366.","journal-title":"Eur J Radiol"},{"key":"1684_CR10","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ijch.201000016","volume":"50","author":"ZR Lu","year":"2010","unstructured":"Lu ZR, Wu X. Polydisulfide based biodegradable macromolecular magnetic resonance imaging contrast agents. Isr J Chem. 2010;50:220\u201332.","journal-title":"Isr J Chem"},{"key":"1684_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/mp900153f","volume":"7","author":"X Wu","year":"2010","unstructured":"Wu X, Jeong EK, Emerson L, Hoffman J, Parker DL, Lu ZR. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers. Mol Pharm. 2010;7:41\u20138.","journal-title":"Mol Pharm"},{"key":"1684_CR12","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1007\/s11095-009-9935-x","volume":"26","author":"X Wu","year":"2009","unstructured":"Wu X, Feng Y, Jeong EK, Emerson L, Lu ZR. Tumor characterization with dynamic contrast enhanced magnetic resonance imaging and biodegradable macromolecular contrast agents in mice. Pharm Res. 2009;26:2202\u20138.","journal-title":"Pharm Res"},{"key":"1684_CR13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cmmi.1520","volume":"8","author":"Z Ye","year":"2013","unstructured":"Ye Z, Wu X, Tan M, Jesberger J, Grisworld M, Lu ZR. Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging. Contrast Media Mol Imaging. 2013;8:220\u20138.","journal-title":"Contrast Media Mol Imaging"},{"key":"1684_CR14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/bmj.1.5794.211","volume":"1","author":"MJ Asbury","year":"1972","unstructured":"Asbury MJ, Gatenby PB, O\u2019Sullivan S, Bourke E. Bumetanide: potent new \u201cloop\u201d diuretic. Br Med J. 1972;1:211\u20133.","journal-title":"Br Med J"},{"key":"1684_CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1020521308985","volume":"30","author":"M Haas","year":"1998","unstructured":"Haas M, Forbush 3rd B. The Na-K-Cl cotransporters. J Bioenerg Biomembr. 1998;30:161\u201372.","journal-title":"J Bioenerg Biomembr"},{"key":"1684_CR16","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-09-4666","volume":"70","author":"BR Haas","year":"2010","unstructured":"Haas BR, Sontheimer H. Inhibition of the sodium-potassium-chloride cotransporter isoform-1 reduces glioma invasion. Cancer Res. 2010;70:5597\u2013606.","journal-title":"Cancer Res"},{"key":"1684_CR17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000339047","volume":"30","author":"J Algharabil","year":"2012","unstructured":"Algharabil J, Kintner DB, Wang Q, Begum G, Clark PA, Yang SS, et al. Inhibition of Na(+)-K(+)-2Cl(\u2212) cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells. Cell Physiol Biochem. 2012;30:33\u201348.","journal-title":"Cell Physiol Biochem"},{"key":"1684_CR18","doi-asserted-by":"crossref","first-page":"L510","DOI":"10.1152\/ajplung.00021.2004","volume":"287","author":"LM Iwamoto","year":"2004","unstructured":"Iwamoto LM, Fujiwara N, Nakamura KT, Wada RK. Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation. Am J Physiol Lung Cell Mol Physiol. 2004;287:L510\u20134.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"1684_CR19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1083\/jcb.114.2.337","volume":"114","author":"R Panet","year":"1991","unstructured":"Panet R, Atlan H. Stimulation of bumetanide-sensitive Na+\/K+\/Cl- cotransport by different mitogens in synchronized human skin fibroblasts is essential for cell proliferation. J Cell Biol. 1991;114:337\u201342.","journal-title":"J Cell Biol"},{"key":"1684_CR20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/00004647-199812000-00011","volume":"18","author":"KS St Lawrence","year":"1998","unstructured":"St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab. 1998;18:1365\u201377.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1684_CR21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10928-013-9315-3","volume":"40","author":"M Ingrisch","year":"2013","unstructured":"Ingrisch M, Sourbron S. Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer. J Pharmacokinet Pharmacodyn. 2013;40:281\u2013300.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1684_CR22","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/mrm.22573","volume":"64","author":"LE Kershaw","year":"2010","unstructured":"Kershaw LE, Cheng HL. Temporal resolution and SNR requirements for accurate DCE-MRI data analysis using the AATH model. Magn Reson Med. 2010;64:1772\u201380.","journal-title":"Magn Reson Med"},{"key":"1684_CR23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0730-725X(90)90055-7","volume":"8","author":"WP Cacheris","year":"1990","unstructured":"Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8:467\u201381.","journal-title":"Magn Reson Imaging"},{"key":"1684_CR24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004424-200102000-00008","volume":"36","author":"S Laurent","year":"2001","unstructured":"Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Investig Radiol. 2001;36:115\u201322.","journal-title":"Investig Radiol"},{"key":"1684_CR25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s11095-013-1188-z","volume":"31","author":"GP Mishra","year":"2014","unstructured":"Mishra GP, Doddapaneni BS, Nguyen D, Alani AW. Antiangiogenic effect of docetaxel and everolimus as individual and dual-drug-loaded micellar nanocarriers. Pharm Res. 2014;31:660\u20139.","journal-title":"Pharm Res"},{"key":"1684_CR26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL. Hypoxia\u2013a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"1684_CR27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/1535-7163.647.3.5","volume":"3","author":"G Powis","year":"2004","unstructured":"Powis G, Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther. 2004;3:647\u201354.","journal-title":"Mol Cancer Ther"},{"key":"1684_CR28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.gde.2009.10.009","volume":"20","author":"GL Semenza","year":"2010","unstructured":"Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev. 2010;20:51\u20136.","journal-title":"Curr Opin Genet Dev"},{"key":"1684_CR29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10555-007-9066-y","volume":"26","author":"D Liao","year":"2007","unstructured":"Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastatis Rev. 2007;26:281\u201390.","journal-title":"Cancer Metastatis Rev"},{"key":"1684_CR30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.semcancer.2008.03.011","volume":"18","author":"JS Fang","year":"2008","unstructured":"Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol. 2008;18:330\u20137.","journal-title":"Semin Cancer Biol"},{"key":"1684_CR31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ccr.2009.01.027","volume":"15","author":"M Paez-Ribes","year":"2009","unstructured":"Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220\u201331.","journal-title":"Cancer Cell"},{"key":"1684_CR32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.drup.2009.03.002","volume":"12","author":"A Rapisarda","year":"2009","unstructured":"Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat. 2009;12:74\u201380.","journal-title":"Drug Resist Updat"},{"key":"1684_CR33","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ejca.2010.02.020","volume":"46","author":"F Azam","year":"2010","unstructured":"Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer. 2010;46:1323\u201332.","journal-title":"Eur J Cancer"},{"key":"1684_CR34","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.2005.10.022","volume":"23","author":"G Gasparini","year":"2005","unstructured":"Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005;23:1295\u2013311.","journal-title":"J Clin Oncol"},{"key":"1684_CR35","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987\u20139.","journal-title":"Nat Med"},{"key":"1684_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oraloncology.2013.10.003","volume":"50","author":"HW Hsu","year":"2014","unstructured":"Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, et al. Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol. 2014;50:19\u201326.","journal-title":"Oral Oncol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1684-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-015-1684-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-015-1684-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T05:26:10Z","timestamp":1691558770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-015-1684-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,4]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s11095-015-1684-4","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,4]]}}}